TP53 and type 1 diabetes mellitus: These experimental data obtained in vitro strongly suggests that this specific p53 activation cannot be recommended as an immunotherapeutic approach in type 1 diabetes patients, either at onset or in the long-term when a beta cell reservoir is still present, since it would promote the activation of Teff cells, which is definitely not beneficial for disease progression.